Menu
Subscribe to our Email Alerts
About Us
Island at a glance
Board
Key Management
Scientific Advisory Board
Collaborations
Science
About ISLA-101
Scientific Publications
Drug repurposing and benefits
Disease and drug terms explained
Investor Centre
Investor Welcome
Clinical programme
ASX Announcements
Presentations
Prospectus
Financial Reports
Share Price Information
Shareholder Services
Investor Fact Sheet
Corporate Governance
Corporate Directory
International Investors
Research Coverage
AGM
Media
News
IslandWatch Newsletter
Contact
Contact Us
Subscribe for Email Alerts
Media
Media
>
News
News
IslandWatch Newsletter
News
Filter by Year:
2025
2024
2023
2022
2021
2020
16-May-2023
Island Pharmaceuticals receives FDA green light for dengue virus ISLA-101 clinical program
17-Apr-2023
Island Pharmaceuticals completes major body of work as it responds to FDA's ISLA-101 requests
9-Feb-2023
Connecting the world to powerful outcomes: Island Pharmaceuticals
9-Feb-2023
Connecting the world to powerful outcomes: David Foster
1-Feb-2023
Island Pharmaceuticals "appreciates" detailed FDA feedback on IND application
23-Jan-2023
Island CEO Dr David Foster discusses FDA feedback on IND for ISLA-101 clinical study
20-Jan-2023
Island Pharmaceuticals receives FDA feedback on IND for Phase 2a clinical trial of dengue vaccine
16-Jan-2023
Island Pharmaceuticals could see a re-rating on positive Phase 2a results in H2CY23: MST Access
5-Jan-2023
Island Pharmaceuticals on track to begin ISLA-101 Phase 2a clinical trial in early 2023: MST Access Research
Previous
1
2
3
.png){kind=logo}
